Higher Burden of Comorbidity Linked to Worse Clinical Outcomes in MS
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 23, 2024 -- For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according to a study published online Sept. 18 in JAMA Neurology to coincide with the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis, held from Sept. 18 to 20 in Copenhagen, Denmark.
Amber Salter, Ph.D., from UT Southwestern Medical Center in Dallas, and colleagues examined the association of comorbidities with disease activity in clinical trials of disease-modifying therapies in populations with MS in a two-stage meta-analytic approach. The cohort study included individual participant data for 16,794 participants with MS from 17 phase 3 clinical trials of MS disease-modifying therapies.
The researchers found that 61.0 percent of the pooled trials had evidence of disease activity (EDA) during the two-year follow-up period. After adjustment for multiple factors, compared with no comorbidity, the presence of three or more comorbidities was associated with an increased risk for EDA (adjusted hazard ratio, 1.14). The risk for EDA was also increased with presence of two or more versus no cardiometabolic conditions (adjusted hazard ratio, 1.21). Increased hazard of EDA was seen in association with one psychiatric disorder (adjusted hazard ratio, 1.07).
"As these findings are coherent with observational studies using different study designs and data sources, evidence suggests that clinicians need to routinely address comorbidity in people with MS," the authors write.
Several authors disclosed ties to the biopharmaceutical industry; the study was based on research using data from pharmaceutical companies.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.